Respiratory Pharmacology Flashcards

1
Q

• Asthma is a complex disorder characterized by?

A
  • Chronic inflammation of the airways
  • Bronchial hyperresponsiveness
  • Airflow obstruction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

• Inflammation of the airways results in?

A
  • Bronchiolar Smooth Muscle Spasm
  • Airway Hyperresponsiveness
  • Airway Edema
  • Increased Mucus Secretion
  • These changes result in airflow obstruction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
Asthma Severity -Symptom Frequency(SF)- Nighttime Awakenings(NA)
Intermittent?
Mild Persistent?
Moderate Persistent?
Severe Persistent?
A

Intermittent: Symptom frequency-≤2 per week Night time awakenings-≤2 times/month

Mild persistent: SF- >2 but not daily, NA- 3-4 times/month

Moderate persistent: SF- Daily, NA->1 time/week but not nightly

Severe persistent SF- Throughout the day, NA- 4-7 times/week

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Types of drugs used to treat asthma?

A
Bronchodilators:
β2 Adrenergic agonists
Anticholinergics
Methylxanthines
Anti-inflammatory Drugs:
Corticosteroids
Release inhibitors
Immunomodulators
Leukotriene modifying agents
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Name three Inhaled short-acting β2 adrenergic agonists

SABAs

A

Albuterol
terbutaline,
pirbuterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Inhaled long-acting β2 adrenergic agonists

LABAs

A

• Salmeterol and formoterol.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Inhaled β2 Adrenergic Agonists: MOA

A

• Bind to and activate β2 adrenergic receptors
on airway smooth muscle cells.
• Activation of β2 receptors stimulates adenylyl
cyclase and increases formation of cAMP.
• cAMP activates protein kinase A which
phosphorylates and inactivates myosin light
chain kinase.
• This results in relaxation of the airway smooth
muscle cells and bronchodilation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Inhaled B2 short acting agonists uses?

A

• SABAs are the DOC for relief of acute asthma
symptoms and prevention of exercise-induced
bronchospasm.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Long acting B2 agonists uses?

A
• LABAs are combined with inhaled
corticosteroids (ICS) for long-term control in
moderate and severe persistent asthma.
• LABAs shouldn’t be used as monotherapy
for long-term control of asthma as they have
no anti-inflammatory action.
• LABAs are not used in the
treatment of acute symptoms
or exacerbations.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

β2 AdrenergicAgonists: Adverse Effects?

A

• Administration of these drug by inhalation
decreases the risk of systemic side effects such
as tachycardia, tremor, and hypokalemia.
• LABAs increase risk of serious asthma related
events (hospitalization, intubation, and
death).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Name an Inhaled Short-Acting Muscarinic Antagonists
(SAMAs)?
Name an Inhaled Long-Acting Muscarinic Antagonists
(LAMAs)?

A

SAMA - Ipratropium

LAMA - Tiotropium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Anticholinergics: MOA?

A

• Inhaled ipratropium and tiotropium block
muscarinic receptors on the airways causing
bronchodilation and reduction of respiratory
secretions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Anticholinergics: Uses?

A

• Ipratropium is less effective than SABAs.
• Ipratropium provides additive benefit to
SABAs in the management of moderate to
severe exacerbations of asthma.
• Ipratropium is the DOC for β-blocker-induced
bronchospasm.
• Tiotropium may be added to ICS for long-term
control of severe persistent asthma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Anticholinergics: Adverse Effects?

A

• These agents are quaternary ammonium
compounds.
• Low access to the systemic circulation and
systemic adverse effects.
• Minor anticholinergic effects, e.g. xerostomia,
might occur.
• They may be safer than SABAs in patients
with cardiovascular disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Name a Methylxanthine? MOA? Uses?

A
• Theophylline
MOA
• Inhibits phosphodiesterase.
• Increase in cAMP evokes bronchodilation
Uses
• Can be given orally or IV.
• Alternative therapy for patients with persistent
asthma.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Theophylline: Adverse Effects?

A

• Largely replaced by β2 agonists and corticosteroids due to narrow therapeutic window, adverse effects, and potential for drug interactions.
• The most common adverse effects are headache, nausea, vomiting, abdominal discomfort, and restlessness.
• At high concentrations: cardiac arrhythmias
and seizures.

17
Q

Anti-Inflammatory Drugs: Corticosteroids?
Inhaled corticosteroids (ICS)?
Systemic corticosteroids?

A

Inhaled corticosteroids (ICS)
• Beclomethasone, budesonide, flunisolide, and
fluticasone

Systemic corticosteroids
• Prednisolone and dexamethasone

18
Q

Corticosteroids: MOA?

A

• Glucocorticoids inhibit phospholipase A2 and
inhibit transcription of COX-2, resulting in
reduced formation of leukotrienes and
prostaglandins.
• Prolonged use of SABAs results in β2
receptors desensitization.
• Corticosteroids prevent or reverse this
desensitization.

19
Q

Corticosteroids: Uses?

A

• ICS are the most effective long-term
control medication in the management of
persistent asthma.
• Oral prednisolone may be added to ICS for
long-term control of severe persistent asthma.
• A short course of systemic corticosteroids is
used for moderate and severe acute
exacerbations of asthma to speed recovery and
to prevent recurrence of exacerbations.

20
Q

Inhaled Corticosteroids: Adverse Effects?

A

• ICS have lower bioavailability than systemic
corticosteroids: risk of potential adverse
effects is reduced.
• Local adverse effects include oropharyngeal
candidiasis, dysphonia, reflex cough and
bronchospasm.
• Long term use may result in osteoporosis and
cataracts. It may cause deceleration of vertical
growth in children.
• Long term use of systemic glucocorticoids may
result in hypercortisolism and Cushing’s
syndrome.

21
Q

Name 2 Anti-Inflammatory Drugs: Release Inhibitors? MOA?

A

• Cromolyn
• Nedocromil
MOA
• Act by inhibiting mast cell degranulation, and
prevent both antigen- and exercise-induced
bronchospasm in asthmatic patients.
• Not useful in managing an acute asthma attack,
because they are not bronchodilators.

22
Q

Release Inhibitors: Uses?

A

• Cromolyn and nedocromil were once widely
used for asthma management, especially in
children, but have now been largely replaced by
other therapies.
• Alternative medications for patients with
mild persistent asthma.
• Also used to prevent exercise-induced
bronchospasm.

23
Q

Release Inhibitors: Adverse Effects?

A

• Throat irritation, cough, mouth dryness.
• Rarely, chest tightness and wheezing.
• Rare side effects include reversible dermatitis,
myositis, or gastroenteritis, pulmonary infiltration
with eosinophilia and anaphylaxis.

24
Q

Name an Anti-Inflammatory Drugs: Immunomodulator? MOA, use, and AE?

A

Omalizumab
• Monoclonal antibody.
• Prevents binding of IgE to basophils and mast
cells.
• Used in the management of patients with
severe persistent asthma with evidence of
allergy.
• Anaphylaxis may occur.

25
Q

Anti-Inflammatory Drugs: Leukotriene-Modifying Agents (LTMAs)
Name 2 Leukotriene Receptor Antagonists (LTRAs):
Name 1 5-Lipoxygenase Inhibitors :

A
Leukotriene Receptor Antagonists (LTRAs)
• Montelukast
• Zafirlukast
5-Lipoxygenase Inhibitors
• Zileuton
• All these drugs are taken orally.
26
Q

Leukotriene-Modifying Agents: MOA?

A

• Leukotriene-modifying agents (LTMAs) interfere
with the pathway of leukotriene mediators,
which are released from mast cells,eosinophils,
and basophils.

27
Q

Leukotriene-Modifying Agents: Uses?

A

• Alternative therapy.
• Used for prevention of exercise-induced
bronchospasm.
• Used in the management of NSAIDexacerbated
respiratory disease (NERD).

28
Q

Leukotriene-modifying agents:

Adverse Effects?

A

• Montelukast: insomnia, anxiety, depression,
suicidal thinking.
• Zileuton: Hepatotoxicity.

29
Q

Acute exacerbations are managed with

quick relief medications:?

A
• Inhaled short-acting beta-2-adrenergic
agonists (SABAs).
• Inhaled short-acting muscarinic
antagonists (SAMAs).
• Systemic corticosteroids.
30
Q
Long term control differences treating different severity of asthma?
Intermittent
Mild persistent
Moderate persistent
Severe persistent
A

Intermittent: No Daily Medications

Mild persistent: Low-dose ICS

Moderate persistent: Low-dose ICS + LABA
OR
Medium-Dose ICS

Severe persistent: Medium-Dose ICS + LABA
OR High-Dose ICS + LABA

31
Q

Define COPD?

A

• COPD is characterized by chronic, progressive,
irreversible obstruction of the airflow.
• Smoking is the most important risk factor for
COPD.
• The three cardinal symptoms of COPD are
dyspnea, chronic cough,and sputum
production.

32
Q

Bronchodilators used in COPD?

A

Short-acting β2 agonists (SABAs) and Short-acting Muscarinic antagonists (SAMAs) : Used for symptomatic relief and in management of acute exacerbations of COPD.

Long-acting β2 agonists (LABAs) and Long-acting muscarinic COPD antagonists (LAMAs) - Used for long-term control of

33
Q

Corticosteroids Used in COPD?

A

Fluticasone and budesonide - Used in the long-term
management of COPD

Oral prednisolone Used in the management of
acute exacerbations of COPD

34
Q

Mucolytic Agents Used in COPD?

A

N-Acetylcysteine
• Breaks disulfide linkages in mucus and lowers
viscosity.

35
Q

What is Allergic Rhinitis?

A

• Inflammation of nasal mucosa induced by
different allergens.
• Characterized by nasal pruritus, sneezing,
rhinorrhea, and nasal congestion.
• Treatment includes allergen avoidance and
pharmacotherapy.

36
Q

Pharmacotherapy of Allergic Rhinitis

A
  • Glucocorticoid nasal sprays
  • Oral antihistamines
  • Cromolyn sodium
  • Montelukast
  • Nasal Decongestants
37
Q

Glucocorticoids: Uses in Allergic Rhinitis? AE?

A
• Glucocorticoid nasal sprays are the first-line
treatment for allergic rhinitis.
AE
• Local irritation of the nasal mucosa
• Nosebleed
• Nasal septal perforation
• Nasopharyngeal candidiasis
38
Q

Name 2 Nasal Decongestants, moa and AE?

A

• α adrenergic agonists.
• Constrict dilated arterioles in the nasal mucosa.
• Should be used no longer than 3 days due to risk
of rebound nasal congestion.

39
Q

Which two drugs can be used for cough? MOA and AE?

A

Codeine and dextromethorphan
• Suppress cough reflex via a direct action on the
cough center in the medulla of the brain.
• Adverse effects: constipation and drowsiness.
• Dextromethorphan is safer and has lower abuse
potential than codeine.